NCT05801237View on ClinicalTrials.gov

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Locally Advanced/Metastatic Solid Tumors
Interventions
DRUG

PE0116&PE0105

This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai HyaMab Biotech Co.,Ltd.

INDUSTRY